Immune biologics such as TNF-alpha inhibitors are among the most commercially successful biopharmaceutical products in the world, presenting a lucrative opportunity for companies to develop biosimilars of these drugs. Recent launches, such as Pfizer’s Inflectra (infliximab-dyyb) in the United States and Celltrion’s Truxima (rituximab) in Europe, are increasing the competition within the immunology space—not just with branded biologics but with the expanding number of biosimilars gaining marketing authorization. For this reason, it is critical that manufacturers/marketers of biosimilars, as well as of branded biologics, understand which factors influence physicians’ uptake of biosimilars. To this end, Decision Resources Group conducted market research with rheumatologists and gastroenterologists in France, Germany, and the United States to gain insights on physicians’ attitude toward biosimilars, the drivers and barriers to biosimilar use, and the expectations for biosimilar adoption.
Key companies mentioned:
Key drugs mentioned: